240 related articles for article (PubMed ID: 25724578)
1. CD133 marks a stem cell population that drives human primary myelofibrosis.
Triviai I; Stübig T; Niebuhr B; Hussein K; Tsiftsoglou A; Fehse B; Stocking C; Kröger N
Haematologica; 2015 Jun; 100(6):768-79. PubMed ID: 25724578
[TBL] [Abstract][Full Text] [Related]
2. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia.
Massa M; Rosti V; Ramajoli I; Campanelli R; Pecci A; Viarengo G; Meli V; Marchetti M; Hoffman R; Barosi G
J Clin Oncol; 2005 Aug; 23(24):5688-95. PubMed ID: 16110028
[TBL] [Abstract][Full Text] [Related]
3. Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging.
Isidori A; Motta MR; Tani M; Terragna C; Zinzani P; Curti A; Rizzi S; Taioli S; Giudice V; D'Addio A; Gugliotta G; Conte R; Baccarani M; Lemoli RM
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1224-32. PubMed ID: 17889360
[TBL] [Abstract][Full Text] [Related]
4. Characterization of serum-free ex vivo-expanded hematopoietic stem cells derived from human umbilical cord blood CD133(+) cells.
Yao CL; Feng YH; Lin XZ; Chu IM; Hsieh TB; Hwang SM
Stem Cells Dev; 2006 Feb; 15(1):70-8. PubMed ID: 16522164
[TBL] [Abstract][Full Text] [Related]
5. Proliferation and differentiation potential of CD133+ and CD34+ populations from the bone marrow and mobilized peripheral blood.
Koutna I; Peterkova M; Simara P; Stejskal S; Tesarova L; Kozubek M
Ann Hematol; 2011 Feb; 90(2):127-37. PubMed ID: 20821012
[TBL] [Abstract][Full Text] [Related]
6. CD133 allows elaborated discrimination and quantification of haematopoietic progenitor subsets in human haematopoietic stem cell transplants.
Radtke S; Görgens A; Kordelas L; Schmidt M; Kimmig KR; Köninger A; Horn PA; Giebel B
Br J Haematol; 2015 Jun; 169(6):868-78. PubMed ID: 25819405
[TBL] [Abstract][Full Text] [Related]
7. Large-scale isolation of CD133+ progenitor cells from G-CSF mobilized peripheral blood stem cells.
Gordon PR; Leimig T; Babarin-Dorner A; Houston J; Holladay M; Mueller I; Geiger T; Handgretinger R
Bone Marrow Transplant; 2003 Jan; 31(1):17-22. PubMed ID: 12621502
[TBL] [Abstract][Full Text] [Related]
8. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
[TBL] [Abstract][Full Text] [Related]
9. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.
Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N
Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810
[TBL] [Abstract][Full Text] [Related]
10. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
11. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
12. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping.
Wuchter C; Ratei R; Spahn G; Schoch C; Harbott J; Schnittger S; Haferlach T; Creutzig U; Sperling C; Karawajew L; Ludwig WD
Haematologica; 2001 Feb; 86(2):154-61. PubMed ID: 11224484
[TBL] [Abstract][Full Text] [Related]
13. Human fetal hepatic progenitor cells are distinct from, but closely related to, hematopoietic stem/progenitor cells.
Chen Q; Khoury M; Limmon G; Choolani M; Chan JK; Chen J
Stem Cells; 2013 Jun; 31(6):1160-9. PubMed ID: 23404852
[TBL] [Abstract][Full Text] [Related]
14. Differential increase of CD34, KDR/CD34, CD133/CD34 and CD117/CD34 positive cells in peripheral blood of patients with acute myocardial infarction.
Grundmann F; Scheid C; Braun D; Zobel C; Reuter H; Schwinger RH; Müller-Ehmsen J
Clin Res Cardiol; 2007 Sep; 96(9):621-7. PubMed ID: 17676354
[TBL] [Abstract][Full Text] [Related]
15. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
16. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
[TBL] [Abstract][Full Text] [Related]
17. Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice.
Saito N; Yamauchi T; Kawano N; Ono R; Yoshida S; Miyamoto T; Kamimura T; Shultz LD; Saito Y; Takenaka K; Shimoda K; Harada M; Akashi K; Ishikawa F
Int J Hematol; 2022 Feb; 115(2):198-207. PubMed ID: 34773575
[TBL] [Abstract][Full Text] [Related]
18. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin.
Bühring HJ; Kuçi S; Conze T; Rathke G; Bartolović K; Grünebach F; Scherl-Mostageer M; Brümmendorf TH; Schweifer N; Lammers R
Stem Cells; 2004; 22(3):334-43. PubMed ID: 15153610
[TBL] [Abstract][Full Text] [Related]
19. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.
Lin EH; Hassan M; Li Y; Zhao H; Nooka A; Sorenson E; Xie K; Champlin R; Wu X; Li D
Cancer; 2007 Aug; 110(3):534-42. PubMed ID: 17594720
[TBL] [Abstract][Full Text] [Related]
20. Clinical isolation and functional characterization of cord blood CD133+ hematopoietic progenitor cells.
Bonanno G; Perillo A; Rutella S; De Ritis DG; Mariotti A; Marone M; Meoni F; Scambia G; Leone G; Mancuso S; Pierelli L
Transfusion; 2004 Jul; 44(7):1087-97. PubMed ID: 15225252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
